New results from #ASCO2026 OPTIMA reinforces the clinical value of Prosigna and the ≤60 threshold to identify patients unlikely to derive meaningful additional benefit from chemotherapy. Although encouraging, the premenopausal sample size in OPTIMA alone is not sufficient to provide a definitive answer: definitive confidence for premenopausal patients will require OPTIMA premenopausal extension OPTIMA-YOUNG data. Congratulations to the OPTIMA team on this great achievement. We are grateful to continue this effort with you, and with all partners and investigators associated with our consortium. #PathForYoung #OptimaYoung

EUROPA DONNA - Why Patient Involvement Matters in Clinical Trial Design @EuropaDonnaEUR @PathforYoung oncodaily.com/voices/europa-… #OncoDaily #Oncology #Cancer #Health #Medicine #BreastCancer #MedX #MedTwitter

Patient Journey in Chemotherapy De-Escalation Trials for Breast Cancer - Tanja Spanic @TanjaSpanic @PathforYoung @MarziaZambon @Carmela_surgery @IR_Macpherson @ines_vazluis @AliceFranzoi oncodaily.com/voices/tanja-s… #OncoDaily #Oncology #Cancer #Health #Medicine #BreastCancer #MedX #MedTwitter #PatientJourney

Stand with science. Listen to patients. Patient voices must shape research—from study design to clinical trials. Through EU-funded projects @DefinitiveTrial & @PathforYoung, we help embed patient engagement in research. #StandWithScience #WorldHealthDay 💗 @WHO